I. Bodrogi

16.4k citations

78 papers · 10.3k indexed · 4 hit papers · h-index 20

Pulmonary and Respiratory Medicine top 0.1%
Molecular Biology top 1%
Oncology top 0.5%
Cancer Research top 0.5%
Surgery top 1%

Co-authors: Oliver Sartor Stéphane Oudard Liji Shen Ivo Kocák Johann S. de Bono Gwénaëlle Gravis Mustafa Özgüroğlu Steinbjørn Hansen
Topics: Testicular diseases and treatments (32 papers)Renal cell carcinoma treatment (10 papers)Cancer Treatment and Pharmacology (8 papers)
Cited by: Pulmonary and Respiratory Medicine Cancer Research Oncology
Journals: New England Journal of Medicine The Lancet Journal of Clinical Oncology
Partner nations: Hungary France United States

In The Last Decade

I. Bodrogi

71 papers receiving 10.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma

2007 2.8k citations I. Bodrogi et al. profile →
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

2010 2.4k citations I. Bodrogi et al. The Lancet profile →
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

2007 1.7k citations Bernard Escudier, A Płużańska et al. The Lancet profile →
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

2000 1.7k citations Hans von der Maase, Steen Werner Hansen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by I. Bodrogi

Since Specialization

Citations

This map shows the geographic impact of I. Bodrogi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Bodrogi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Bodrogi more than expected).

Fields of papers citing papers by I. Bodrogi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Bodrogi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Bodrogi. The network helps show where I. Bodrogi may publish in the future.

Co-authorship network of co-authors of I. Bodrogi

This figure shows the co-authorship network connecting the top 25 collaborators of I. Bodrogi. A scholar is included among the top collaborators of I. Bodrogi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Bodrogi. I. Bodrogi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study 2023 ·Journal of Clinical Oncology ·Hans von der Maase,Steen Werner Hansen,J.T. Roberts,Luigi Dogliotti,T. Oliver,Malcolm J. Moore,I. Bodrogi,Peter Albers,Alexander Knuth,Christian Lippert,Pierre Kerbrat,Pedro Sánchez‐Rovira,Peter Wersäll,Simon Cleall,D. Roychowdhury,(unknown),Carla Visseren‐Grul,Pierfranco Conté	19
2	Neutrophil-to-lymphocyte ratio in primary mediastinal germ cell tumors: A retrospective analysis of >20 years single institution experience 2020 ·Current Problems in Cancer ·Lajos Géczi,Barna Budai,(unknown),(unknown),I. Bodrogi,(unknown)	2
3	Outcome of Restarted Sunitinib Treatment in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Trial and Combined Case Reports from Literature 2017 ·Pathology & Oncology Research ·(unknown),Barna Budai,(unknown),(unknown),(unknown),I. Bodrogi,Lajos Géczi	2
4	A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Plus Docetaxel/Prednisolone in Patients with Hormone-Refractory Prostate Cancer 2009 ·Cancer Biotherapy and Radiopharmaceuticals ·J Horti,Anders Widmark,Arnulf Stenzl,Miriam Hatsue Honda Federico,Raymond P. Abratt,(unknown),G. Pover,I. Bodrogi	39
5	A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992) 2008 ·Annals of Oncology ·Christine Théodore,Iwona Skoneczna,I. Bodrogi,Michael Leahy,J. Martijn Kerst,Laurence Collette,Katrin van der Ven,Sandrine Marréaud,Rebecca Oliver	78
6	Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialbreakdown → 2007 ·The Lancet ·Bernard Escudier,A Płużańska,P. Koralewski,Alain Ravaud,Sergio Bracarda,Cezary Szczylik,Christine Chevreau,M. Filipek,Bohuslav Melichar,Emilio Bajetta,В. А. Горбунова,Jacques‐Olivier Bay,I. Bodrogi,Agnieszka Jagiełło-Gruszfeld,N. Moore	1722
7	Expression and prognostic value of the lung resistance-related protein (LRP) in germ cell testicular tumors. 2004 ·PubMed ·(unknown),Lajos Géczi,Zoltán Doleschall,I. Bodrogi,Orsolya Csuka,Miklós Kásler,Mihály Bak	6
8	HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel 2004 ·Breast Cancer Research and Treatment ·Angelo Di Leo,Stephen Chan,Marianne Paesmans,Kay Friedrichs,Tamás Pintér,V. Cocquyt,Elizabeth Murray,I. Bodrogi,Euan Walpole,Bernard Lespérance,S Korec,John Crown,Peter Simmonds,Gϋnter von Minckwitz,Jean-Yves Leroy,Virginie Durbecq,Jorma Isola,Matti Aapro,Martine Piccart,Denis Larsimont	121
9	Clinical relevance of HER-2/neu expression in germ-cell testicular tumors. 2004 ·PubMed ·(unknown),Lajos Géczi,I. Bodrogi,József Tóth,Orsolya Csuka,Miklós Kásler,Mihály Bak	15
10	Increased predisposition to cancer in brothers and offspring of testicular tumor patients 2004 ·Pathology & Oncology Research ·S. Gundy,(unknown),(unknown),I. Bodrogi	23
11	Expression of HER-2/neu in testicular tumors. 2003 ·PubMed ·(unknown),Lajos Géczi,I. Bodrogi,József Tóth,Mihály Bak	14
12	[Lung resistance protein analysis in testicular cancer]. 2002 ·PubMed ·(unknown),Lajos Géczi,Zoltán Doleschall,(unknown),I. Bodrogi,Mihály Bak	1
13	Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Studybreakdown → 2000 ·Journal of Clinical Oncology ·Hans von der Maase,Steen Werner Hansen,J.T. Roberts,Luigi Dogliotti,T. Oliver,Malcolm J. Moore,I. Bodrogi,Peter Albers,Alexander Knuth,Christian Lippert,Pierre Kerbrat,Pedro Sánchez‐Rovira,Peter Wersäll,Simon Cleall,D. Roychowdhury,(unknown),Carla Visseren‐Grul,Pierfranco Conté	1678
14	[Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer]. 1999 ·PubMed ·M. Gershanovich,(unknown),Daniel de Castro,H. Lurie,(unknown),M Jeffrey,Franco Buzzi,I. Bodrogi,Holger Ludwig,(unknown),N. J. O’Higgins,Gilles Romieu,(unknown),M. Lassus	1
15	Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. 1998 ·Journal of Clinical Oncology ·Stan B. Kaye,Graham M. Mead,Sophie D. Fosså,M.H. Cullen,R deWit,I. Bodrogi,C. van Groeningen,Richard Sylvester,Laurence Collette,Sally Stenning,Linda de Prijck,Élodie Lallemand,(unknown)	120
16	Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer 1998 ·Annals of Oncology ·M. Gershanovich,H.A. Chaudri,(unknown),H. Lurie,Antonino Bonaventura,M Jeffrey,Franco Buzzi,I. Bodrogi,H Ludwig,Peter Reichardt,N. J. O’Higgins,Gilles Romieu,Philip W. Friederich,M. Lassus	206
17	Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy 1995 ·International Urology and Nephrology ·L Kisbenedek,I. Bodrogi,(unknown),(unknown),Péter Tenke,J Horti	8
18	Persistence of Chromosomal Aberrations in Blood Lymphocytes of Testicular Cancer Patients 1992 ·Oncology ·S. Gundy,(unknown),I. Bodrogi,A. Czeizel	17
19	Persistence of Chromosomal Aberrations in Blood Lymphocytes of Testicular Cancer Patients 1990 ·Oncology ·S. Gundy,(unknown),I. Bodrogi,A. Czeizel	9
20	Characteristics and Chemotherapeutic Sensitivity of a Human Testicular Cancer Grown in Artificially Immunosuppressed Mice 1985 ·Oncology ·(unknown),L. Kópper,I. Bodrogi,J Sugár,K. Lapis,Sabine Eckhardt	2

About I. Bodrogi

I. Bodrogi is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine, having authored 78 papers that have together received 10.3k indexed citations. Recurring topics across this work include Testicular diseases and treatments (32 papers), Renal cell carcinoma treatment (10 papers) and Cancer Treatment and Pharmacology (8 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (6.4k citations), Cancer Research (2.9k citations) and Oncology (3.6k citations). I. Bodrogi has collaborated with scholars based in Hungary, France and United States. Frequent co-authors include Oliver Sartor, Stéphane Oudard, Liji Shen, Ivo Kocák, Johann S. de Bono, Gwénaëlle Gravis, Mustafa Özgüroğlu, Steinbjørn Hansen, Jean-Pascal Machiels and Mary J. MacKenzie. Their work appears in journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact